Skip to content

High Calorie High Protein Nutrition Supplementation in Advanced Heart Failure

Impact of a High Energy and High Protein Nutrition Supplementation Intervention on Outcomes in Patients With Advanced Heart Failure

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05219708
Enrollment
33
Registered
2022-02-02
Start date
2022-04-05
Completion date
2024-06-30
Last updated
2024-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Brief summary

In this study, the investigators will determine the impact of a high calorie and high protein nutrition supplementation strategy on quality of life in participants with advanced heart failure. The investigators hypothesize that participants with advanced heart failure who receive the high calorie high protein nutrition supplementation strategy will experience an improvement in quality of life compared to those patients that receive usual care.

Detailed description

This is a single center, prospective randomized open with blinded endpoint (PROBE) trial with an individual follow-up time of 30 days duration designed to determine the impact of a high calorie high protein nutritional supplementation strategy on quality of life and functional outcomes in adults with malnutrition advanced systolic heart failure. 48 participants will be randomized in a stratified fashion by gender and Subjective Global Assessment (SGA) class (B versus C). Study subjects will receive a calorie and protein nutritional supplement, Ensure Original, manufactured by Abbott laboratories for 30 days after hospital discharge. The study site will be Columbia University Irving Medical Center. Investigators will be blinded to group assignment and dietary recalls until the completion of the study.

Interventions

DIETARY_SUPPLEMENTCalorie protein supplement

Participants assigned to the intervention group will receive the calorie and protein supplement (i.e. Ensure Original) to be consumed twice daily between meals for 30 days in addition to standard of care for heart failure

OTHERControl

Standard of care for heart failure

Sponsors

Columbia University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients aged ≥ 18 years * Hospitalized at Columbia University Irving Medical Center/New York Presbyterian Hospital * Left ventricular ejection fraction \<=40% * At least mild malnutrition as determined by the Subjective Global Assessment (SGA)

Exclusion criteria

* Inability to eat orally * Inability to eat independently * History of dysphagia * Allergy to nutritional supplement * Need for inotrope and/or mechanical support at hospital discharge * Listed for heart transplant * Insulin dependent diabetes and/or most recent A1c \>7% * Having two or more results of a serum potassium \>5.0 mmol/L during hospitalization or history of serum potassium \>6.0 mmol/L, and/or at an excessive risk of hyperkalemia as judged by the investigators * Severe renal insufficiency (estimated glomerular filtration rate \<30 ml/min/1.73m\^2 at discharge) * Cirrhosis * History of bariatric surgery * Nursing home residence * History of persistent noncompliance with treatment recommendations as judged by the investigators

Design outcomes

Primary

MeasureTime frameDescription
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) ScoreUp to 30 daysThe Kansas City Cardiomyopathy Questionnaire (KCCQ) is a self-administered questionnaire to assess quality of life in heart failure. Scores range from 0-100 with a higher score indicating better quality of life.

Other

MeasureTime frameDescription
Change in handgrip strengthUp to 30 daysHandgrip strength as measured by Jamar Hydraulic Hand Dynamometer
Change in Short Physical Performance Battery (SPPB) ScoreUp to 30 daysSPPB measures functional capacity. Scores range from 0 (lowest physical performance) to 12 (highest physical performance).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026